Thomas and Massagué showed that systemic neutralization of TGF-β in vivo results in tumour eradication, associated with an increase in CD8+ T-cell mediated tumour-cell-specific cytotoxicity [71]. This evidence concerns the gene TGFB1 and neoplasm.